A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult Volunteers Receiving Type 1 Monovalent Oral Poliovirus Vaccine (mOPV1).

Trial Profile

A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult Volunteers Receiving Type 1 Monovalent Oral Poliovirus Vaccine (mOPV1).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs V 073 (Primary) ; Poliovirus vaccine live oral
  • Indications Poliomyelitis
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors ViroDefense
  • Most Recent Events

    • 08 Dec 2016 Primary endpoint of time from initiation of treatment to virus excretion negativity as measured by virus culture of stool sample has been met, according to results published in the Journal of Infectious Diseases.
    • 08 Dec 2016 Results published in the Journal of Infectious Diseases
    • 08 Sep 2012 Planned number of patients changed from 108 to 144.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top